These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 28408242)
41. Heterogeneous pathological outcomes after experimental pH1N1 influenza infection in ferrets correlate with viral replication and host immune responses in the lung. Vidaña B; Martínez J; Martínez-Orellana P; García Migura L; Montoya M; Martorell J; Majó N Vet Res; 2014; 45(1):85. PubMed ID: 25163545 [TBL] [Abstract][Full Text] [Related]
42. Evolution of Therapeutic Antibodies, Influenza Virus Biology, Influenza, and Influenza Immunotherapy. Chaisri U; Chaicumpa W Biomed Res Int; 2018; 2018():9747549. PubMed ID: 29998138 [TBL] [Abstract][Full Text] [Related]
43. Adjunctive therapies and immunomodulating agents for severe influenza. Hui DS; Lee N Influenza Other Respir Viruses; 2013 Nov; 7 Suppl 3(Suppl 3):52-9. PubMed ID: 24215382 [TBL] [Abstract][Full Text] [Related]
45. Decline in intravenous immunoglobulin titer against influenza virus A/H2N2 derived from donors in Japan. Yunoki M; Kubota-Koketsu R; Shioda T J Med Virol; 2023 Mar; 95(3):e28685. PubMed ID: 36939012 [TBL] [Abstract][Full Text] [Related]
46. Intravenous immunoglobulin (IVIG) attenuates antibody binding in acute haemorrhagic immunopneumonitis in a rat model of complement-dependent lung injury. Dantas M; Costa RS; Barbosa JE; Graeff MS; Sarti W; De Carvalho IF Clin Exp Immunol; 2000 Jul; 121(1):139-45. PubMed ID: 10886251 [TBL] [Abstract][Full Text] [Related]
48. An addition to treatment options for avian influenza A H5N1? Baz M; Subbarao K Lancet Infect Dis; 2015 Mar; 15(3):251-3. PubMed ID: 25662593 [No Abstract] [Full Text] [Related]
49. Pulmonary administration of IgG loaded liposomes for passive immunoprophylaxy. Dreffier C; Ramisse F; Dubernet C Int J Pharm; 2003 Mar; 254(1):43-7. PubMed ID: 12615407 [TBL] [Abstract][Full Text] [Related]
50. Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Hui DS; Lee N; Chan PK Antiviral Res; 2013 Jun; 98(3):410-6. PubMed ID: 23578727 [TBL] [Abstract][Full Text] [Related]
51. Advancing new vaccines against pandemic influenza in low-resource countries. Berlanda Scorza F Vaccine; 2017 Sep; 35(40):5397-5402. PubMed ID: 28410815 [TBL] [Abstract][Full Text] [Related]
52. In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity. Wu NC; Grande G; Turner HL; Ward AB; Xie J; Lerner RA; Wilson IA Nat Commun; 2017 May; 8():15371. PubMed ID: 28504265 [TBL] [Abstract][Full Text] [Related]
54. Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: The test-negative design case-control study with different control groups. van Doorn E; Darvishian M; Dijkstra F; Donker GA; Overduin P; Meijer A; Hak E Vaccine; 2017 May; 35(21):2831-2839. PubMed ID: 28412077 [TBL] [Abstract][Full Text] [Related]
55. A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines. Van Hoeven N; Fox CB; Granger B; Evers T; Joshi SW; Nana GI; Evans SC; Lin S; Liang H; Liang L; Nakajima R; Felgner PL; Bowen RA; Marlenee N; Hartwig A; Baldwin SL; Coler RN; Tomai M; Elvecrog J; Reed SG; Carter D Sci Rep; 2017 Apr; 7():46426. PubMed ID: 28429728 [TBL] [Abstract][Full Text] [Related]
56. Early administration of neuraminidase inhibitors in adult patients hospitalized for influenza does not benefit survival: a retrospective cohort study. Choi SH; Kim T; Park KH; Kwak YG; Chung JW; Lee MS Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1673-1677. PubMed ID: 28417272 [TBL] [Abstract][Full Text] [Related]
57. Airway proteases: an emerging drug target for influenza and other respiratory virus infections. Laporte M; Naesens L Curr Opin Virol; 2017 Jun; 24():16-24. PubMed ID: 28414992 [TBL] [Abstract][Full Text] [Related]
58. Multifaceted Tissue-Protective Functions of Polyvalent Immunoglobulin Preparations in Severe Infections-Interactions with Neutrophils, Complement, and Coagulation Pathways. Schmidt C; Weißmüller S; Heinz CC Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002022 [TBL] [Abstract][Full Text] [Related]
59. Sepsis - it is all about the platelets. Cox D Front Immunol; 2023; 14():1210219. PubMed ID: 37350961 [TBL] [Abstract][Full Text] [Related]
60. Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza. Vanderven HA; Wentworth DN; Han WM; Peck H; Barr IG; Davey RT; Beigel JH; Dwyer DE; Jain MK; Angus B; Brandt CT; Mykietiuk A; Law MG; Neaton JD; Kent SJ; JCI Insight; 2023 Jul; 8(14):. PubMed ID: 37289541 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]